# Amblyotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amblyotech

- Industry: Software
- Headquarters: Atlanta, US
- Website: www.amblyotech.com
- Total disclosed funding: $0.1M
- Latest round: Seed (May 19, 2016)
- Investors on record: 1

## About

Amblyotech, Inc. specializes in developing digital therapies for amblyopia, utilizing advanced gaming and video technology to enhance visual function in affected patients.Founded in 2013 and headquartered in Atlanta, US, Amblyotech, Inc. focuses on addressing amblyopia through innovative digital therapy solutions. The company was acquired by Novartis AG in April 2020, which marks a strategic pivot to leverage Novartis's resources for further development. Amblyotech has engaged in 6 deals, with a total amount raised of USD 0.73 mn from its SEED funding round.Amblyotech's core product, developed under Novartis, is a digital therapy designed for amblyopia treatment, combining active gaming and passive video technology via 3-D glasses. This unique approach, featuring dichoptic display, aims to improve visual coordination by presenting different images to each eye. The therapy targets children and adults with amblyopia, addressing quality-of-life challenges stemming from untreated vision issues. Novartis plans to commercialize this solution in key global markets, including North America, Europe, and Asia, reaching healthcare professionals, patients, and caregivers.Details on Amblyotech's revenue structure remain undisclosed. However, the company operates primarily through partnerships with healthcare providers and educational institutions, implying a business model that includes direct sales to clinics and hospitals. The innovative nature of the therapy suggests pricing strategies that accommodate both private and public healthcare systems. Collaboration with organizations like Ubisoft and McGill University supports the development and commercialization of their digital therapy, aligning with the aim to transform medical treatment through technology.Amblyotech's growth strategy includes the integration of its digital therapy into Novartis's broader product line following its acquisition. The acquisition in April 2020 is expected to drive further development and expansion into new markets, including targeted efforts in North America, Europe, and Asia. The recent funding raised will support these initiatives, although specific details on upcoming product launches have not been disclosed.

## Funding rounds

- Seed, May 19, 2016, $0.1M — Jumpstart Health Investors

## Investors

- Jumpstart Health Investors (https://capitalatlas.ai/funds/jumpstart-health-investors) — Seed